MRVI
MARAVAI LIFESCIENCES HOLDINGS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 26 Maravai LifeSciences reported full-year 2025 revenue of $185.7 milli…
- Jun 3 ▲ Maravai LifeSciences refinanced its prior credit agreement by enteri…
- Jun 9 to Jun 10 ▼ 2 days of insider sells: $254.0K by 1 insider, avg $5.08
- Nov 4 ▲ Earnings: MRVI Q3 2026 Earnings: EPS $-0.03 (+48.1% vs est)
- Nov 12 ▲ Keybanc upgrades
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider sold $254.0K.
- InstitutionsBULLISH
Q3 2026: 30 added (2 new), 10 trimmed or exited.
- AnalystsBULLISH
10 of 15 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.084 → −$0.039 over 90 days. 1 up, 0 down in 30 days.
- Short sellersSTEADY
Short interest +5.3% to 14.05M shares. 6.8 days to cover, ≈5.4% of shares.
- TrendUPTREND
0% above its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| FMR LLC | DOUBLED | $52.9M |
| Qube Research & Technologies Ltd | DOUBLED | $22.3M |
| MORGAN STANLEY | ADD | $20.8M |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | ADD | $19.1M |
| MARSHALL WACE, LLP | ADD | $15.6M |
| BNP PARIBAS FINANCIAL MARKETS | ADD | $10.8M |
| HRT FINANCIAL LP | ADD | $10.5M |
| JPMORGAN CHASE & CO | NEAR_EXIT | $3.4M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
15 analystsPrice is below the lowest target. Median implies +28%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 12, 2026 | Keybanc UPGRADE | Overweight |
| Sep 9, 2026 | UBS MAINTAIN | Neutral |
| Aug 7, 2026 | Wells Fargo MAINTAIN | Overweight |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Brust Bernd Chief Executive Officer Nov 9, 2026 | TAX W/H | $220.0K |
Asarpota Rajesh Chief Financial Officer Oct 30, 2026 | TAX W/H | $46.2K |
Brust Bernd Chief Executive Officer Oct 8, 2026 | TAX W/H | $217.3K |
Asarpota Rajesh Chief Financial Officer Sep 30, 2026 | TAX W/H | $41.8K |
Brust Bernd Chief Executive Officer Sep 8, 2026 | TAX W/H | $214.1K |
Asarpota Rajesh Chief Financial Officer Aug 31, 2026 | TAX W/H | $42.0K |
Brust Bernd Chief Executive Officer Aug 10, 2026 | TAX W/H | $182.2K |
Asarpota Rajesh Chief Financial Officer Jul 30, 2026 | TAX W/H | $36.0K |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.04 | -$0.06–-$0.02 | +12.3% | $51.2M |
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
5 filings · 1 bullish · 0 bearish · 2 mixed · 2 neutral- NEUTRAL SC 13GSep 29, 2026
Millennium Management LLC filed a Schedule 13G disclosing a 5.2% passive stake in Maravai…
Monitor for any future conversion of this 13G to a 13D, which would signal activist intent. Millennium's repeated 13G filings suggest ongoing passive accumulation; a shift in filing type would be a…
- MIXED INST-CLUSTERJun 14, 2026
During Q1 2026, six institutional investors increased their MRVI positions (net +$2.3M) while…
The buying is modest in absolute dollar terms and dominated by passive/quantitative asset managers, not event-driven funds. Monitor for a catalyst (e.g., pipeline update or earnings) that could…
- BULLISH 8-KJun 3, 2026
Maravai LifeSciences refinanced its prior credit agreement by entering into a new $150.0 million…
Debt paydown eliminates near-term refinancing risk. Monitor upcoming quarterly filings for revenue/EPS trends and leverage ratio to see if full benefits materialize.
- NEUTRAL DEFA14AApr 27, 2026
Maravai LifeSciences Holdings, Inc. filed a DEFA14A to add Inline XBRL tagging to its definitive…
No trading action warranted. This is a purely technical correction to add XBRL tagging. Monitor the actual Annual Meeting on May 26, 2026, for voting outcomes, but no market-moving information is…
All MRVI filing & press-release reports (5)
- SC 13G reportSep 29, 2026
- INST-CLUSTER reportJun 14, 2026
- 8-K reportJun 3, 2026
- DEFA14A reportApr 27, 2026
- 8-K reportFeb 26, 2026